Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
869,565
-
Total 13F shares
-
95,444
-
Share change
-
+95,444
-
Total reported value
-
$164,193
-
Price per share
-
$1.73
-
Number of holders
-
10
-
Value change
-
+$164,193
-
Number of buys
-
10
Institutional Holders of Protagenic Therapeutics, Inc.\new - Common Stock, par value $0.0001 per share (PTIX) as of Q1 2023
As of 31 Mar 2023,
Protagenic Therapeutics, Inc.\new - Common Stock, par value $0.0001 per share (PTIX) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
95,444 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, FNY Investment Advisers, LLC, STATE STREET CORP, ADVISOR GROUP HOLDINGS, INC., Tower Research Capital LLC (TRC), UBS Group AG, WELLS FARGO & COMPANY/MN, MORGAN STANLEY, and BANK OF AMERICA CORP /DE/.
This page lists
10
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.